Nevertheless, these predictors of response have been proposed based only on preclinical data and in specific types of cancer, and have not been clinically validated, with the exception of the loss of PTEN expression, that was used in clinical trials as a marker to evaluate glioblastoma sensitivity to rapamycin treatment [235]. The gene discussed is PTEN; the disease is glioblastoma.